GPT and anemia: For patients who received the NP regimen, the incidence of grade 3–4 hematologic toxicities (leukopenia, anemia or thrombocytopenia), oral mucositis, vomiting and both liver and renal function abnormalities (ALT elevation or sCr elevation) was 44.8%, 14.9%, 25.4%, 31.3%, 31.3% and 20.9%, respectively.